BioTrinity 2025: Over 800 Professionals Convene to Paint a Picture of Hope for UK Life Sciences
03 April 2025
BioTrinity 2025: Over 800 Professionals Convene to Paint a Picture of Hope for UK Life Sciences
- BioTrinity 2025 welcomed over 800 delegates, matching the highest-ever attendance set in 2024.
- Three action-packed tracks covered investment trends, regulatory shifts, and cutting-edge scientific advancements.
- Nearly 10,000 meetings requested, with 2,000 in-person, fuelling partnerships and growth in UK life sciences.
Oxford and London, UK, 03 April 2025: OBN’s annual BioTrinity conference, now in its 19th year, held this week in London, matched the record-breaking attendance of 2024’s event. More than 800 delegates from innovative life sciences companies, investors, pharma companies, science parks and professional services organisations came together, and the event gave them all invaluable opportunities to network, connect and build partnerships to drive sector growth, gain business insight and celebrate the sector’s latest remarkable breakthroughs.
The event boasted three action-packed tracks running simultaneously. The Business & Investment track saw experts and panel discussions take fascinating deep dives into a range of topics, including how macro-environment factors impact growing R&D companies, insight into how the Inflation Reduction Act influences external markets, and the role of the British Business Bank in supporting UK life sciences. Running in parallel were two Science tracks spanning 14 speciality areas, where companies shared their latest research and pioneering Innovation.
Held in the spacious Convene, 133 Houndsditch, the conference gave delegates plenty of room to network and hold impromptu meetings. Demonstrating OBN’s commitment to helping its members forge new connections, the Partnering room was a place where delegates could meet and network. The room had a constant hum of discussion as parties came together to explore business growth. In total, nearly 10,000 meetings were requested across the two days (plus a third virtual partnering day), with 2,000 taking place in person. They were all designed to fuel deal-making in the sector.
Following the success of their introduction at 2024’s event, BioTrinity 2025 saw the return of the academic poster presentations. Here, in a fast-paced environment, life science academics and early-career professionals delivered high-speed pitches of their concepts to the BioTrinity audience while displaying a poster promoting their offering.
Looking back over the two-day event, Stuart Rose, CEO of OBN said: “For me, five key themes came from BioTrinity 2025. Politically, there are the challenges of the National Insurance hike, and difficulties with navigating R&D tax credits. But in June, we will have the Invest 2035 white paper, in which life sciences is a core target area. Secondly is investment; in 2024 private investment in the UK life sciences was the second strongest on record and there looks to be continued easing of the private market. Thirdly, the regulatory environment is in a state of flux and opportunity. The FDA is going through challenging times due to DOGE and at the same time new leadership in the MHRA could present a real opportunity for a more pro-business approach from the UK regulator being open for business. With leadership, the fact that some investors are mandating leadership coaching for their companies’ leaders is hugely positive and session explored the power of humility, and the willingness to learn and grow. And finally, the UK has a tiny fraction of the world’s population, yet we have 40% of the world’s top 10 universities, deliver 8.5% of the world’s best R&D citations, and that actually sits us more than 50% per capita better than the US, the world’s biggest market.
“I look at all of these factors, and believe there will be increasing opportunities ahead for life sciences in the UK.”
Connect with OBN digitally:
LinkedIn https://www.linkedin.com/company/obnuk/
For media enquiries please contact:
Sophie Beech, Marketing & Communications Manager Sophie.beech@obn.org.uk
About OBN – www.obn.org.uk
OBN is a life sciences network, focused on catalysing growth across the industry. Our 500+ member companies are located throughout the UK and benefit from our events, networking, partnering, purchasing, advising and advocacy activities
